The ESOT Council conducted an inquiry on new immunosuppressive substan
ces in order to help keep members of ESOT informed. Thirty-one pharmac
eutical companies were sent a questionnaire indicating whether they we
re developing new immunosuppressive substances/antibodies. Sixteen com
panies responded: 11 furnished information on 16 substances; 5 said th
at they were not developing any new immunosuppressive agents. Fifteen
companies did not reply at all. The results of the first inquiry are r
eported here.